Contact: Peter Tarr
Cold Spring Harbor Laboratory
Caption: The candidate drug MSI-1436 (trodusquemine) inhibits HER2-positive tumor formation and metastasis through its inhibition of the enzyme PTP1B. Here, its effect on HER2-positive lung metastasis is shown: image at far left is untreated; dark areas are tumor metastases. The drug at two doses is shown to clear the metastatic lesions (dosage in center image is half that in right image).
Credit: Tonks lab/Cold Spring Harbor Laboratory
Usage Restrictions: give credit please
Related news release: Team validates potentially powerful new way to treat HER2-positive breast cancer